Ind-Swift Limited

Equities

INDSWFTLTD

INE788B01028

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:49 2024-05-03 am EDT 5-day change 1st Jan Change
24.46 INR -1.96% Intraday chart for Ind-Swift Limited -1.09% +36.80%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ind-Swift Limited Approves Execution of Loan Facility Agreement CI
Ind-Swift Limited Announces Cessation of Sri Prakash Sharma as Independent Director, Effective March 31, 2024 CI
Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent Director CI
Ind-Swift Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited. CI
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories MT
The Office of the Regional P.F. Commissioner -Ii Dmg Regional Office, Karnal Imposed Damages and Interests on Ind-Swift Limited CI
Ind-Swift Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Ind-Swift Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Ind-Swift Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Ind-Swift Approves Appointment of Sh. Bhupinder Singh as an Independent Director CI
Ind-Swift Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Ind-Swift Launches Products in Qatar MT
Ind-Swift Limited Launches Finished Dosages Products CI
Ind-Swift Limited Appoints Ginny Uppal as Company Secretary and Compliance Officer CI
Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2022 CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Ind-Swift Forms New Subsidiary in Kenya MT
Ind-Swift Ltd. Announces Demise of Jatendar Kumar Kakkar, Non-Executive Independent Director CI
Ind-Swift Limited Announces the Resignation of Amrender Kumar Yadav as Company Secretary & Compliance Officer CI
Ind-Swift Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Ind-Swift Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021 CI
Ind-Swift Limited Reports Earnings Results for the First Quarter Ended June 30, 2021 CI
Chart Ind-Swift Limited
More charts
Ind Swift Limited is an India-based pharmaceutical manufacturing and marketing company. The Company operates in both domestic and export markets. It is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The Company is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. It operates through various divisions, such as Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte. The Company also provides a range of COVID19 products, including masks, travel kits, hand sanitizers, and gloves. It has also launched two products, Stevia (natural sweetener) and Hangover (helps avoid alcoholic hangover). The Company also has five plants in India.
More about the company